FDA rejects Hengrui-Elevar liver cancer drug combo for third time

July 10, 2026 01:42 PM EDT ChinaFDA+ FDA re­jects Hen­grui-El­e­var liv­er can­cer drug com­bo for third time Zachary Brennan Senior Editor For the third time in about two years, the FDA has cit­ed man­u­fac­tur­ing de­fi­cien­cies in re­ject­ing a drug com­bi­na­tion from Jiang­su Hen­grui Phar­ma­ceu­ti­cals and El­e­var … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER